Onychomycosis Lecture Flashcards

1
Q

Onychomycosis

A

Most common nail disorder

Toenails&raquo_space;> fingernails

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Dermatophytes

A

Trichophyton rubrum

Trichophyton mentagrophytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Yeast

A

Candida albicans

Candida parapsilosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Nondermatophytes

A

Aspergillus

Scopulariopsis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why treat?

A
Quality of life
Physiological stress
Pain
Inflammation
Peripheral circulation
Foot ware
Infection potential
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Types of onychomycosis

A

DISTAL SUBUNGUAL ONYCHOMYCOSIS
White superficial onychomycosis
Proximal subungual onychomycosis
Candida Onychomycosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Distal Subungual Onychomycosis

A

Most common
Infection begins in the distal area of the nail bed (tip of the toe)
THICK toenail

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

White superficial

A

Toe nail infection only
Involves the surface of the nail –> not a thicker nail
Nail is soft, dry, and easily scraped off

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Proximal Subungual Onychomycosis

A

Infection that beings at the nail bed and moves out

Leads to separation from nail bed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dystrophic

A

Nail deformities

- Increased risk of infection in immunocompromised and diabetic patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Candida Onychomycosis

A
Immunocompromised
Seen in dishwashers
Nails appear opaque and does not crumple
Yellow-brown in collor
FINGER NAILS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Differential diagnosis

A
Psoriasis
Pseudomonal infections
Medications
Exzema
Dermatitis
Trauma
Ischemic conditions (poor blood flow)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

People at risk

A

Diabetes
Immunosuppressant and systemic antibiotics
HIV/AIDS: younger age –> proximal subungual onychomycosis
Geriatrics >60
Institutional living
Athletes
Health clubs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical presentation/symptoms

A

Hyperkeratosis (thickening of the nail)
Discoloration of the nail (white or brown)
Brittleness
Onycholysis (separation of the nail from the bed
Paronychial inflammation
Recurrent tinea pedis
Pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Diagnosis

A
History/clinical symptoms
KOH prep of nail clippings
Fungal culture
Nail biopsies
- Need test as well as physical observations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ideal agents

A
Good concentration in the nail bed
High clinical/mycologic cure rate
Low rate of relapse
Short term therapy
Few ADR's and interactions
Cost effective
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treatment options

A
Nail removal
Topiocal therapy (ineffective)
Griseofulvin
Ketaconazole (DO NOT USE)
Itraconazole
Fluconazole
Terbinafine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Topical Nail Therapy

A

Nail lacquers (ciclopirox- PenLac)
Antifungal agents: solutions or creams (clotrimazole, tolnaftate, terbinafine) or powders (tolnaftate
– Low cure rate and high relapse rate

19
Q

History of high transaminase levels or have liver disease and want something for fungal infections?

A

PenLac bc others raise transaminase levels

20
Q

Cons of Topical Nail therapy

A

Cannot penetrate harden nail mass
Requires multiple daily applications and long duration of therapy
- Can be used with other oral treatments

21
Q

Griseofulvin

A

First oral agent; Fungistatic
Microsize: need to take with a fatty meal to increase adsorption
Ultramicrosize: Increased absorption
- Monitor Baseline AST, ALT, and CBC and repeat AST and ALT if treatment last >6 wks

22
Q

Dosage of Griseofulvin

A

500 mg QD-BID

23
Q

Griseofulvin Disadvantages

A

High rate of resistance, high rate of relapse, low cure rate, long duration, intolerable adverse drug reactions
ADR’s: skin rashes, urticaria, GI, photosensitivity, toxic epidermal necrolysis (sore throat, fever, rash)
- Potential cross reactive with penicillin

24
Q

Griseofulvin Drug Interactions

A

Anticoagulants, oral contraceptives, cyclosporine and salicylates
Phenobarbital decrease serum concentrations

25
Q

Fluconazole (Diflucan)

A

Fungistatic –> inhibits the synthesis of ergosterol

Toe nails

26
Q

Fluconazole (Diflucan) Advantages

A

Good nail bed and matrix penetration
Detect in toenails 6 months after
Good absorption not influence by gastric acid, food, antacids or H2 blockers

27
Q

Fluconazole (Diflucan) Disadvantages

A

Lacks indication

Not extensively studied

28
Q

Fluconazole (Diflucan) Dosage

A

150, 300, or 450 mg week for 3 months
3-12 months of treatment
80% excreted unchanged via urine

29
Q

Fluconazole (Diflucan) Monitor & Interaction

A

Baseline AST, ALT, CBC; remonitor >6 wk therapy
Increases the effects of warfarin, cyclosporine, theophyline, phenytoin, sulfonylureas
QT prolongation and decreases oral contraceptives

30
Q

Fluconazole (Diflucan)ADR’s

A

GI- nausea, diarrhea and ab pain, elevated liver enzymes

Pulse dosing decrease incidence

31
Q

Intraconzaole (Sporanox)

A

Fungistatic- inhibits the synthesis of ergosterol
For onychomycosis; good concentration in nail matrix and bed
Detectable for 6 months after

32
Q

Intraconzaole (Sporanox) Dosage

A

Toenails: 200 mg daily for 12 weeks
Fingernails: 200 mg BID for 3 days per month for 2 months (separated by 3 weeks)

33
Q

Intraconzaole (Sporanox) Monitor

A

Baseline AST, ALT, CBC; recheck monthly

34
Q

Intraconzaole (Sporanox) Drug Interactions

A

Warfarin, H2 blockers, PPI, DDI, Ritonavir, Indiavir, Benzodiazepines, Lovastatin, Simvastatin, Cyclosporine, Tacrolimus, Phenytoin, Phenobarbital, carbamazepine, rifamycins

35
Q

Intraconzaole (Sporanox) ADR’s

A
GI- nausea, vomiting, diarrhea, ab pain
Headache
Dizziness
Rash
ELEVATED LIVER ENZYMES
36
Q

Intraconzaole (Sporanox) FDA Warnings

A

Hepatoxicity
CHF, cardiac dysfunction or a history of CHF
- Discontinue if signs or symptoms of CHF

37
Q

Intraconzaole (Sporanox) Disadvantages

A

Drug interactions
Expensive
Must be taken with full meal
Acidic environment for absorption - no antacids, H2 blockers, PPIs; need achlorhydria - soda increases adsorption

38
Q

Terbinafine (Lamisil)

A

First line therapy
FDA indicaiton
More effective than itraconzaole
Fungicidals

39
Q

Terbinafine (Lamisil) Dosage

A

Fingernail: 250 mg QD for 6 weeks
Toenails: 250 mg QD for 12 weeks

40
Q

Terbinafine (Lamisil) FDA warnings

A

Hepatotocicity (rare)

  • Liver failure and death
  • Not indicated for chronic or active hepatic disease
  • NO LIVER DISEASE PATIENTS*
41
Q

Terbinafine (Lamisil) Monitor and interactions

A

Baseline AST, ALT, CBC; recheck after >6 wk of treatment
Tricyclic antidepressants, SSRI’s (fluoxetine, paroxetine)
Venlafaxine and cyclosporine

42
Q

Terbinafine (Lamisil) ADRs

A

GI- diarrhea, ab pain, nausea, and flaulence
Rash
TASTE DISTRUBANCES
ELEVATED LIVER ENZYMES

43
Q

Terbinafine (Lamisil) Advantages

A

Fewer drug interactions, fewer ADR’s, fungicidal activity, pregnancy category B

44
Q

Therapeutic considerations

A
Concomitant disease states (don't treat liver disease patients)
Drug interactions (azoles)
ADR's (terbinafine and fluconazole = better tolerated)
How much they cost